Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, multi-center, open-label prospective phase II clinical study
designed to evaluate the efficacy and safety of nab-paclitaxel and S-1 in patients with
locally advanced pancreatic cancer. A total of 60 subjects who meet the criteria will be
treated with nab-paclitaxel and S-1. The primary endpoint is 6 months progression free
survival rate, and secondary endpoints include objective response rate, overall survival,
progression free survival and toxicities.